CliniMACS Prodigy® Instrument

Brochures/posters

• CliniMACS Prodigy® Adherent Cell Culture System Differentiation of human pluripotent stem cells into mesencephalic dopaminergic progenitor cells
• Chimeric Antigen Receptor T cells
• Changing the way of generating engineered T cells - CliniMACS Prodigy® T Cell Transduction Process
• The CliniMACS Prodigy flyer
• Generation of gene-engineered hematopoietic stem cells - CliniMACS Prodigy® Hematopoietic Stem Cell Engineering System
• Generation of gene-engineered T cells via electroporation and/or transduction
• CliniMACS Prodigy® Adherent Cell Culture System - GMP-compliant human mesenchymal stem cell expansion process
• The CliniMACS Prodigy® Platform - Master the complexity of clinical cell manufacturing
• CliniMACS Prodigy® - Adherent Cell Culture Differentiation of human pluripotent stem cells into cardiomyocytes
• CliniMACS® Prodigy - Customized Application Service
• CliniMACS Prodigy® Adherent Cell Culture System GMP-compliant human pluripotent stem cell expansion process
• Generation of gene-engineered T cells - CliniMACS T cell transduction process

Scientific posters

• Automation of hematopoietic stem cell transduction: Results of a head-to-head comparison between a manual and an automated procedure
• Scalable process for standardized generation of human PSC-derived cardiomyocytes
• Efficient GMP-compliant expansion of mesenchymal stromalcells (MSCs) from umbilical cord, bone marrow, and adiposetissue using a closed cultivation system
• GMP-compliant expansion of mesenchymal stromal cells (MSCs) using the CliniMACS Prodigy® and xeno-free MSC-Brew GMP Medium
• Bringing automation to large-scale manufacturing of TCR modified T cells for adoptive cell therapy
• Fully integrated closed-system expansion and differentiation of pluripotent stem cells towards mesencephalic dopaminergic progenitor cells
• Standardized QC assays and (automated) expansion of pluripotent stem cells
• Polyclonal T cell activation and expansion tool for clinical-scale manufacturing of gene-modified T cells
• Automated manufacturing of gene-engineeredT cells under serum-free conditions
• Effective retroviral transduction of primary T cells and hematopoieticstem cells using the soluble transduction enhancer: Vectofusin-1®
• Automated clinical-scale retroviral transduction of T cells in a functionally closed system
• Safety assessment of MACS® GMP T Cell TransAct™, a robust and potent polyclonalT cell activation and expansion tool for clinical-scale manufacturing of gene-modified T cells

App notes/customer reports

• Enrichment and stimulation of primary blood dendritic cell subsets - CliniMACS Prodigy® BloodDC PreDepletion and CliniMACS Prodigy BloodDC Enrichment and Culture
• Large-scale manufacturing of transduced T cells - CliniMACS Prodigy® T Cell Transduction – Large Scale
• Generation of tumor-reactive T cells - CliniMACS Prodigy® Tumor Reactive T Cell Process
• Depletion of CD3⁺ cells with and without enrichment of CD56⁺ cells

References

• CliniMACS Prodigy® Platform - selected references
• CliniMACS Prodigy® - selected references
• CliniMACS Prodigy T Cell Transduction - selected references

• Lock, D. et al. (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum. Gene Ther. 28(10): 914-925
• Klöß, S. et al. (2017) Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of Anti-CD123-CAR-expressing effector cells. Hum. Gene Ther. 28(10): 897-913
• Dolgin, E. (2017) The key to unlocking CARs. Nat. Biotechnol. 35(10): 891-892
• Tarnowski, J. et al. (2017) Delivering advanced therapies: the big pharma approach. Gene Ther. 24(9): 593-598
• Fraser, A. R. et al. (2017) Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis. Cytotherapy 19(9): 1113-1124
• Pello, O. M. et al. (2017) BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur. J. Haematol. 98(6): 632-634
• Skorska, A. et al. (2017) GMP-conformant on-site manufacturing of a CD133(+) stem cell product for cardiovascular regeneration. Stem Cell Res. Ther. 8(1): 33
• Levine, B. L. et al. (2016) Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4: 92-101
• Priesner, C. et al. (2016) Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs. Hum. Gene Ther. 27(10): 860-869
• Priesner, C. et al. (2016) Comparative analysis of clinical-scale IFN-γ-positive T cell enrichment using partially and fully integrated platforms. Front Immunol 7: 393
• Mock, U. et al. (2016) Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18(8): 1002-1011
• Takashi, I. et al. (2016) Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation. J. Exp. Med. 213(9): 1865-1880
• Wang, X. and Rivière, I. (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics 3: 16015
• Walker, A. and Johnson, R. (2016) Commercialization of cellular immunotherapies for cancer. Biochem. Soc. Trans. 44(2): 329-332
• Hümmer, C. et al. (2016) Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure. J. Transl. Med. 14: 76
• Stroncek, D. F. et al. (2016) Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion 56(2): 511-517
• Bunos, M. et al. (2015) Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Vox sang. 109(4): 387-393
• Spohn, G. et al. (2015) Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 17(10): 1465-1471
• Kumaresan, P. et al. (2015) Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. J. Vis. Exp. 104: e52808
• Sorg, N. et al. (2015) Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies. Transfusion 55(6): 1275-1282
• Granzin, M. et al. (2015) Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 17(5): 631-632
• Apel, M. et al. (2013) Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture. Chemie Ingenieur Technik 85: 103-110